Xiaobo Sun Selected Research

notoginsenoside R1

1/2021	Notoginsenoside R1 Improves Cerebral Ischemia/Reperfusion Injury by Promoting Neurogenesis via the BDNF/Akt/CREB Pathway.
2/2020	Correction: Zhou, P., et al. Notoginsenoside R1 Ameliorates Diabetic Retinopathy through PINK1-Dependent Activation of Mitophagy. Cells, 2019, 8, 213.
1/2019	Notoginsenoside R1 Protects db/db Mice against Diabetic Nephropathy via Upregulation of Nrf2-Mediated HO-1 Expression.
1/2019	Notoginsenoside R1 Ameliorates Diabetic Retinopathy through PINK1-Dependent Activation of Mitophagy.
4/2018	Notoginsenoside R1 prevents H9c2 cardiomyocytes apoptosis against hypoxia/reoxygenation via the ERs/PI3K/Akt pathway.
2/2018	Notoginsenoside R1 ameliorates diabetic encephalopathy by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation.
1/2018	Notoginsenoside R1 Protects Against Diabetic Cardiomyopathy Through Activating Estrogen Receptor α and Its Downstream Signaling.
2/2016	Cardioprotective effects of Notoginsenoside R1 against ischemia/reperfusion injuries by regulating oxidative stress- and endoplasmic reticulum stress- related signaling pathways.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaobo Sun Research Topics

Disease

22	Reperfusion Injury 01/2022 - 02/2012
19	Inflammation (Inflammations) 01/2022 - 04/2015
17	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022 - 02/2012
14	Neoplasms (Cancer) 03/2021 - 01/2011
10	Insulin Resistance 01/2022 - 04/2014
10	Atherosclerosis 01/2021 - 01/2014
10	Neuromyelitis Optica (Devic's Disease) 01/2021 - 04/2015
7	Body Weight (Weight, Body) 01/2022 - 04/2014
7	Hypoxia (Hypoxemia) 01/2022 - 01/2013
7	Hyperlipidemias (Hyperlipidemia) 01/2022 - 01/2013
7	Cardiotoxicity 03/2021 - 01/2013
7	Cognitive Dysfunction 01/2021 - 08/2013
6	Infections 12/2022 - 01/2014
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 02/2017
6	Fibrosis (Cirrhosis) 01/2022 - 01/2017
6	Ischemic Stroke 01/2022 - 12/2018
6	Brain Ischemia (Cerebral Ischemia) 01/2021 - 01/2018
6	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 06/2011
6	Anti-N-Methyl-D-Aspartate Receptor Encephalitis 07/2020 - 01/2017
6	Multiple Sclerosis 10/2019 - 01/2016
5	Diabetic Cardiomyopathies 01/2022 - 01/2017
5	Myocardial Infarction 01/2022 - 01/2012
5	Diabetic Retinopathy (Retinopathy, Diabetic) 03/2021 - 01/2019
4	Hypertrophy 01/2022 - 04/2014
4	Obesity 01/2022 - 01/2019
4	Atherosclerotic Plaque (Atheroma) 05/2021 - 01/2015
4	Type 2 Diabetes Mellitus (MODY) 01/2021 - 05/2006
4	Central Nervous System Diseases (CNS Diseases) 07/2020 - 01/2014
4	Mitochondrial Diseases (Mitochondrial Disease) 01/2020 - 08/2009
4	hypoglycemic encephalopathy 01/2019 - 02/2018
3	Hyperglycemia 01/2022 - 01/2018
3	Stroke (Strokes) 04/2021 - 12/2018
3	Meningoencephalitis 01/2021 - 01/2019
3	Acute Lung Injury 01/2021 - 01/2020
3	Non-alcoholic Fatty Liver Disease 11/2020 - 04/2015
3	Hemorrhage 04/2020 - 01/2018
3	Wounds and Injuries (Trauma) 01/2020 - 01/2015
3	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 02/2015
3	Coronary Disease (Coronary Heart Disease) 01/2020 - 02/2007
3	Infarction (Infarctions) 10/2019 - 01/2018
3	Necrosis 10/2019 - 01/2018
3	Chemical and Drug Induced Liver Injury 05/2019 - 12/2018
2	Encephalitis (Encephalitis, Rasmussen) 03/2022 - 07/2020
2	Squamous Cell Carcinoma of Head and Neck 01/2022 - 01/2021
2	Heart Diseases (Heart Disease) 01/2022 - 01/2020
2	Seizures (Absence Seizure) 01/2022 - 01/2019
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 12/2021 - 10/2019
2	Diabetic Nephropathies (Diabetic Nephropathy) 11/2021 - 01/2019

Drug/Important Bio-Agent (IBA)

15	Pharmaceutical PreparationsIBA 01/2021 - 01/2017
13	Proteins (Proteins, Gene)FDA Link 12/2022 - 12/2014
10	LipidsIBA 01/2022 - 01/2013
9	CalciumIBA 01/2022 - 01/2018
9	Neuroprotective AgentsIBA 01/2021 - 01/2018
8	AntioxidantsIBA 01/2022 - 01/2015
8	InflammasomesIBA 12/2021 - 01/2018
8	CytokinesIBA 03/2021 - 04/2014
8	notoginsenoside R1IBA 01/2021 - 02/2016
7	Myelin-Oligodendrocyte GlycoproteinIBA 01/2022 - 04/2017
7	EnzymesIBA 01/2022 - 01/2016
7	SaponinsIBA 01/2022 - 01/2018
7	Caspase 3 (Caspase-3)IBA 03/2019 - 08/2009
6	ginsenoside Rb1IBA 01/2022 - 01/2017
6	Apolipoproteins E (ApoE)IBA 05/2021 - 01/2014
6	AntibodiesIBA 07/2020 - 04/2015
6	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 07/2020 - 01/2017
6	Immunoglobulin G (IgG)IBA 10/2019 - 01/2017
6	oxidized low density lipoproteinIBA 01/2019 - 01/2015
5	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 04/2014
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 12/2018
4	Blood Glucose (Blood Sugar)IBA 01/2022 - 12/2018
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2020
4	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2020 - 12/2014
4	Therapeutic UsesIBA 01/2020 - 04/2014
4	C-Reactive ProteinIBA 10/2019 - 02/2007
4	Proanthocyanidins (Procyanidins)IBA 04/2016 - 08/2013
3	Antiviral Agents (Antivirals)IBA 12/2022 - 01/2014
3	Insulin (Novolin)FDA Link 01/2022 - 04/2014
3	gypenoside XVIIIBA 11/2021 - 02/2017
3	Indicators and Reagents (Reagents)IBA 01/2021 - 09/2016
3	gastrodinIBA 01/2021 - 01/2018
3	Phytoestrogens (Phytoestrogen)IBA 01/2021 - 02/2017
3	hydroxysafflor yellow AIBA 01/2021 - 01/2020
3	ginsenoside Rg1IBA 01/2021 - 12/2018
3	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2012
3	Malondialdehyde (Propanedial)IBA 01/2020 - 01/2018
3	Retinaldehyde (Retinal)IBA 01/2020 - 07/2017
3	Interleukin-6 (Interleukin 6)IBA 12/2019 - 01/2019
3	Estrogen ReceptorsIBA 04/2018 - 01/2017
2	AdipokinesIBA 01/2022 - 01/2022
2	calenduloside EIBA 01/2022 - 12/2021
2	ChemokinesIBA 01/2022 - 01/2016
2	Peptides (Polypeptides)IBA 01/2022 - 06/2011
2	GinsenosidesIBA 01/2022 - 01/2019
2	Metformin (Glucophage)FDA LinkGeneric 11/2021 - 01/2018
2	Atorvastatin (Lipitor)FDA Link 05/2021 - 03/2020
2	oil red OIBA 05/2021 - 01/2015

Therapy/Procedure

9	Therapeutics 11/2021 - 01/2013
3	Immunotherapy 01/2022 - 03/2020
3	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2021 - 01/2014
3	Aftercare (After-Treatment) 01/2020 - 01/2017